From: High expression of p62/SQSTM1 predicts shorter survival for patients with pancreatic cancer
Variable | Univariable analysis | Multivariable analysisa | ||||
---|---|---|---|---|---|---|
HR | 95% CI | p | HR | 95% CI | p | |
Age | ||||||
< 65 years | 1 | 1 | ||||
≥65 years | 1.59 | 0.65–3.89 | 0.312 | 1.40 | 0.39–5.09 | 0.608 |
Sex | ||||||
Female | 1 | 1 | ||||
Male | 0.76 | 0.33–1.77 | 0.525 | 0.59 | 0.19–1.86 | 0.366 |
Tumor location | ||||||
Head | 1 | |||||
Others | 1.46 | 0.32–6.55 | 0.624 | N.A. | ||
Tumor stage | ||||||
pT1–2 | 1 | 1 | ||||
pT3–4 | 1.26 | 0.55–2.92 | 0.587 | 1.15 | 0.30–4.37 | 0.839 |
Differentiation | ||||||
Medium or high | 1 | 1 | ||||
Low | 1.19 | 0.45–3.13 | 0.728 | 1.05 | 0.27–4.09 | 0.942 |
Lymph node metastasis | ||||||
N0 | 1 | 1 | ||||
N1 | 1.09 | 0.45–2.62 | 0.847 | 0.90 | 0.31–2.61 | 0.841 |
Adjuvant chemotherapy | ||||||
No | 1 | 1 | ||||
Yes | 0.42 | 0.15–1.18 | 0.101 | 0.37 | 0.10–1.34 | 0.130 |
p62 | ||||||
Low | 1 | 1 | ||||
High | 2.88 | 1.17–7.11 | 0.022 | 3.83 | 1.24–11.84 | 0.020 |
LC3 | ||||||
Low | 1 | |||||
High | 0.64 | 0.25–1.63 | 0.349 | N.A. | ||
NRF2 | ||||||
Low | 1 | |||||
High | 1.02 | 0.43–2.45 | 0.957 | N.A. |